Howard J F Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 2017; 16: 976–86—In this Article, (published online Oct 20), the p value for one of the datapoints in figure 2 should be 0·0007. Additionally, in the sentence ‘Half of all patients reported their worst MGFA classification since diagnosis as class IV or V’ on page 6, the citation at the end of the sentence should be ‘appendix’.

中文翻译：

---

更正

Howard JF Jr，Utsugisawa K，Benatar M等。Eculizumab在抗乙酰胆碱受体抗体阳性的难治性重症肌无力（REGAIN）中的安全性和有效性：3期，随机，双盲，安慰剂对照，多中心研究。柳叶刀神经科学2017; 16： 976-86 —在本文（10月20日在线发布）中，图2中数据点之一的p值应为0·0007。此外，在第6页的句子“所有患者中有一半报告自诊断为IV或V类以来，他们的MGFA分类最差”，句子结尾处的引用应为“附录”。